Comparative Pharmacology
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus PROMETHAZINE W DEXTROMETHORPHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus PROMETHAZINE W DEXTROMETHORPHAN.
LEVOCETIRIZINE HYDROCHLORIDE vs PROMETHAZINE W/ DEXTROMETHORPHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocetirizine is a selective peripheral histamine H1-receptor antagonist. It inhibits the effects of histamine at the H1 receptor, reducing allergic symptoms such as itching, sneezing, and rhinorrhea. It has lower affinity for central H1 receptors and anticholinergic properties compared to first-generation antihistamines.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist and antiemetic; dextromethorphan is a non-opioid antitussive that acts as an NMDA receptor antagonist and sigma-1 receptor agonist.
Oral, 5 mg once daily in the evening.
5 mL (containing promethazine 6.25 mg and dextromethorphan 15 mg) orally every 4-6 hours as needed, not to exceed 30 mL (promethazine 37.5 mg, dextromethorphan 90 mg) per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 7–8 hours in healthy adults; prolonged to 20–24 hours in renal impairment (CrCl <40 mL/min); clinically, stable levels require 2–3 days.
Promethazine: 9-16 h; dextromethorphan: 3-5 h (extensive metabolizers), 30-50 h (poor metabolizers). Clinical context: dosing interval typically 4-6 h for dextromethorphan; promethazine accumulates with repeated dosing.
Approximately 85% renal excretion as unchanged drug via glomerular filtration and tubular secretion, 12.9% fecal excretion, <1% biliary.
Renal: promethazine ~6% unchanged, dextromethorphan ~0.5% unchanged; metabolites primarily renal. Biliary/fecal: minor routes for both.
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic